Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma

Amit Mittal1,5, Mike Wang1,2,4,5,*, Aurobind Vidyarthi3, Diana Yanez1, Gabriela Pizzurro1, Durga Thakral1, Erin Tracy3 & Oscar R. Colegio3,4,6

Cutaneous squamous cell carcinomas (cSCC) are among the most commonly diagnosed malignancies, causing significant morbidity and mortality. Tumor-associated macrophage (TAM) expression of arginase is implicated in tumor progression, and therapeutic use of arginase inhibitors has been studied in various cancers. However, investigating potential cSCC immunotherapies including arginase inhibition in pre-clinical models is hampered by the lack of appropriate tumor models in immunocompetent mice. PDV is a cSCC cell line derived from chemical carcinogenesis of mouse keratinocytes. PDVC57 cells were derived from a PDV tumor in C57BL/6 (B6) mice. Unlike PDV, PDVC57 tumors grow consistently in B6 mice, and have increased TAMs, decreased dendritic and T cell intra-tumor infiltration. Arginase inhibition in cSCC tumors using Nω-hydroxy-nor-arginine (nor-NOHA) reduced tumor growth in B6 mice but not immunodeficient Rag1-deficient mice. nor-NOHA administration increased dendritic and T cell tumor-infiltration and PD-1 expression. The combination of nor-NOHA and anti-PD-1 therapy with nivolumab enhanced anti-PD-1 therapeutic efficacy. This study demonstrates the therapeutic potential of transcutaneous arginase inhibition in cSCC. A competent immune microenvironment is required for tumor growth inhibition using this arginase inhibitor. Synergistic co-inhibition of tumor growth in these results, supports further examination of transcutaneous arginase inhibition as a therapeutic modality for cSCC.

Published data and clinical experience suggest that innate and adaptive immunity play crucial roles in the development, progression, and prognosis of cSCC. Solid organ transplant recipients (SOTR) require lifelong systemic immunosuppression to prevent graft rejection, and compared with the general population, SOTRs are approximately 100-times more likely to develop cSCC5. The cSCC in SOTR are generally more aggressive, being more invasive and metastatic6,7. Within the tumor microenvironment, cSCC demonstrate higher macrophage and T cell infiltration compared to normal skin or non-malignant keratinocyte-derived lesions such as actinic keratoses or keratoacanthomas8,9.

Tumor-associated macrophages (TAMs) are associated with poor prognosis in various cancers, including lung, colorectal, liver, and breast cancers10-15. TAMs facilitate tumor progression, proliferation and metastasis by stimulating angiogenesis and inhibiting antitumor T cell responses16,17. TAM expression of the enzyme arginase, which catalyzes hydrolysis of L-arginine to produce urea and L-ornithine and depletes extracellular L-arginine, has been implicated in tumor progression18-20. However, the mechanisms by which arginase are critical to tumor growth have yet to be fully elucidated.

While arginase inhibition provides a potentially useful tool in treating SCC, investigating the cSCC tumor microenvironment in preclinical models presents a major challenge, as there is a lack of implantable syngeneic...
cSCC tumor models in immunocompetent mice. Implantable tumor models have been used extensively in T cell-deficient mice at the expense of accurately modeling innate and adaptive immune interactions. In this study, we used PDVC57, an cSCC cell line derived from the C57BL/6-derived PDV cSCC cell line via in vivo passage, to serve as a murine tumor model for analyzing the immune microenvironment in cSCC21,22. In contrast to implantation of PDV cells, which develop tumors in ~ 10% of C57BL/6 mice, PDVC57 cells develop tumors in 100% of C57BL/6 mice. We investigated the role of arginase in PDVC57 tumor progression in vivo using transcutaneous inhibition of arginase. Inhibition of arginase activity was effective in reducing tumor growth in vivo. We determined that PD-1, a T cell activation/exhaustion marker and the prototypical checkpoint inhibitor target, was upregulated in the setting of small molecule inhibition of arginase. The combination of transcutaneous arginase inhibition with anti-PD-1 therapy demonstrated therapeutic synergy in the reduction of PDVC57 cSCC tumor growth.

Results

PDV and PDVC57 are genetically related murine squamous carcinoma cell lines that grow similarly in vitro but are distinct in their growth in vivo. To better characterize the PDVC57 cell line, PDV and PDVC57 cells were cultured and whole exome sequencing was performed. Sequencing demonstrated that PDV and PDVC57 share a majority (2800/3640, 76.9%) of their exonic variants compared to normal blood leukocytes (Fig. 1A, upper) and the two cell lines have similar mutational burdens (PDV: 2896 exonic mutations; PDVC57: 2726 exonic mutations. Supplemental Fig. 1). The cultured cells appeared morphologically different (Fig. 1A, lower) and flow cytometric analysis revealed that PDVC57 cells were significantly larger and more granular than PDV cells (Supplemental Fig. 2). Finally, the cell lines had similar logistic growth curves that demonstrated no significant difference between the two, with PDVC57 having a slightly shorter but not significantly different calculated doubling time (Fig. 1B).

To develop and characterize this syngeneic cSCC tumor model, we injected 1, 5, or 10 million PDVC57 cells intradermally into the flanks of five C57BL/6 (B6) mice per group. All five mice in the 5 and 10 million cell injections developed tumors, and 3/5 (60%) of the mice in 1 million-cell injection developed tumors (Supplemental Fig. 3). The resultant tumors were harvested at day 21 (Fig. 2A) and either embedded in paraffin for histopathological analysis or frozen for immunofluorescence. The histology of the injected tumors demonstrated cords and nests of malignant epithelial cells with nests of keratinizing cells consistent with cutaneous squamous differentiation23 (Fig. 2B). Under immunofluorescence microscopic imaging, the tumors broadly expressed p63, a marker of squamous differentiation often used in the identification of SCCs and usually only found in the basal layer of the epidermis and the cutaneous appendages, such as the hair follicles24–26 (Fig. 2C,D).

Given that the PDVC57 cells consistently developed tumors in B6 mice with 5-million-cell injections, we intradermally injected two sets of 10 mice with 5 million PDV versus PDVC57 cells. Comparing PDV and PDVC57 intradermal tumors in B6 mice, injected PDV tumors grew more slowly, reached a growth peak at approximately day 15, and subsequently regressed (Fig. 3A). None of the ten B6 mice bearing PDV tumors...
reached the experimental endpoint and were all censored at day 42, and the tumor weights at the conclusion of the experiment were significantly lower than PDVC57 tumors (Fig. 3C,D). These differences were not demonstrated when the cells are injected into Rag1-deficient mice (B6.129S7-Rag1tm1Mom/J) mice, which lack mature T and B cells (Fig. 3B–D).

Transcutaneous arginase inhibition is sufficient to inhibit PDVC57 tumor growth. The growth of PDV tumors in immunodeficient Rag1 knockout (KO) mice (B6.129S7-Rag1tm1Mom/J) in contrast to the immunocompetent B6 mice demonstrates that PDV tumors are immunologically rejected in B6 mice; furthermore, PDVC57 tumors may modulate the immune microenvironment to promote tumor growth27. Flow cytometry of PDV and PDVC57 tumors injected into B6 mice showed that PDVC57 tumors contained more tumor-associated macrophages (TAM), fewer tumor-infiltrating dendritic cells, and fewer tumor-infiltrating CD4+ and CD8+ T cells (Fig. 4A–C). The increase in TAMs in SCC has been shown to lead to a worse prognosis, and previous work and existing literature had shown that TAM-derived arginase is important in promoting tumor growth20,28,29. In agreement, we observed that PDVC57 tumors demonstrated greater arginase activity compared to PDV tumors (Fig. 4D).

Using a novel transcutaneous delivery model of arginase inhibition, Nω-hydroxy-nor-arginine (nor-NOHA) was topically applied to the cSCCs formed after intradermal PDVC57 injection. Compared to vehicle control, daily application of 5 mM nor-NOHA significantly decreased the volume and weight of PDVC57 tumors in WT B6 mice (Fig. 5A,B). This difference was not demonstrated in immunodeficient Rag1 KO mice (Fig. 5C,D), while arginase activity assays confirmed that nor-NOHA was able to successfully decrease arginase activity in both experimental groups (Fig. 5E,F).
Transcutaneous arginase inhibition and systemic PD-1 inhibition are synergistic in decreasing PDVC57 tumor growth. We demonstrated that direct cytotoxicity of nor-NOHA was not the mechanism of tumor growth suppression as an in vitro kill curve assay demonstrated a LD50 of 18.91 mM nor-NOHA in PDVC57 cells (Supplemental Fig. 4)—almost fourfold higher than the concentration used in the in vivo treatments. Further, as shown above, transcutaneously delivered nor-NOHA did not induce a significant reduction of tumor growth in vivo in Rag1 KO mice (Fig. 5). Therefore, we sought to characterize the immunomodulatory effects of arginase inhibition. In B6 mice injected with PDVC57 tumors, nor-NOHA application increased CD4+ and CD8+ T cells, as well as CD11c+ MHCII+ dendritic cells within the tumor (Fig. 6A,B). Interestingly, proportions of CD3+ T cells expressing PD-1 also increased after treatment (Fig. 6A).

Due to the increased PD-1 expression in nor-NOHA treated PDVC57 tumors, combination therapy with the PD-1 inhibitor nivolumab was tested. The combination therapy further decreased PDVC57 tumor growth (Fig. 7A–D) and final tumor weight (Fig. 7E–H), compared to either nor-NOHA or nivolumab alone. In addition, the combination treatment increased intratumoral CD4+ and CD8+ T cells, and CD11c+ MHCII+ dendritic cells in comparison to either nor-NOHA or nivolumab treatment, alone (Fig. 8A–C).

Discussion
Immunotherapy is a rapidly emerging field in the treatment of cSCC and has largely focused on eliciting an adaptive immune response. The rationale behind treating cSCC by activating adaptive immunity is based on the observation that cSCC exhibits a high load of neoepitope mutations induced by ultraviolet (UV) radiation, which should stimulate cytotoxic T cells. This mutational load was demonstrated in both PDV and PDVC57 cell lines through whole exome sequencing and prediction of more than 1900 neoepitope-contributing exonic variants (Supplementary Fig. 1). Cemiplimab is an anti-PD-1 checkpoint inhibitor recently approved in 2018 by the United States Food and Drug Administration for the treatment of metastatic and locally advanced cSCC. Pembrolizumab, another PD-1 inhibitor, is currently being studied as another possible immunotherapeutic in
cSCC. However, only half of patients with unresectable locally advanced and/or metastatic cSCC responded to cemiplimab checkpoint inhibition. As such, other targets in the immune response against cSCC may be exploited for further therapy.

TAM-derived arginase is increasingly becoming an important therapeutic target in various cancers. The degradation of arginine, in which arginase plays an integral part, has been demonstrated to lead to T cell suppression. Clinically, the upregulation of arginase activity and the expression of ARG1, has been correlated with various cancers, such as gastric, breast, renal cell, and head and neck squamous cell carcinomas. In this study, we sought to utilize transdermal arginase inhibition as a method of non-invasive drug delivery that is particularly applicable to cSCC, a skin cancer.

Testing this hypothesis required an appropriate murine model with an intact immune system. However, as noted previously, there is a lack of preclinical models available for testing of potential therapeutics, which drastically hinders the further development of new therapies. The current gold standard for analysis of cSCC in immunocompetent mice is chemical carcinogenesis using a two-stage protocol of 7,12-dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) application. This method is limited by the multiple-month delay between initiation of carcinogenesis and observation of clinically apparent tumors. Many of the tumors that develop are also more similar, in terms of histology and growth characteristics, to squamous papillomas than true cSCC. Several injectable murine cSCC tumor models have been derived from DMBA or TPA treatment. HaCa4 were transformed by HaMSV-transforming retrovirus and TPA. CarB and CarC were derived from two anaplastic skin carcinomas induced by DMBA and TPA. The PDV cell line was derived from primary C57BL/6 mouse epidermal cells treated in vitro with DMBA. None of these cell lines form tumors consistently in immunocompetent syngeneic mice. Herein we characterized PDVC57, a cell line derived by in vivo passaging of the PDV cell line. Morphologically and genetically, we have shown that PDVC57 is a distinct cSCC cell line. Notably, both the PDV and PDVC57 cell lines bear the HrasQ61L mutation, a well-characterized driver mutation in some human cSCC. PDVC57 was able to consistently form cSCC tumors.

Figure 4. PDVC57 tumors recruit more tumor-associated macrophages and fewer T cells and dendritic cells than PDV tumors. (A) Percentage of intratumoral CD45+ leukocytes that are CD11b+ F4/80+, indicating tumor-associated macrophages; significantly higher in PDVC57 tumors. (B) Percentage of intratumoral CD4+ leukocytes that are CD3+ CD4+ or CD3+ CD8+, indicating tumor-infiltrating T cells; CD3+ CD4+, CD3+ CD8+ cells significantly lower in PDVC57 tumors. (C) Percentage of intratumoral CD45+ leukocytes that are CD11c+ MHCII+, indicating tumor-infiltrating dendritic cells; significantly lower in PDVC57 tumors. (D) Arginase activity in units of catalytic activity (U) as assessed by enzymatic fluorometric assay; significantly higher in PDVC57 tumors. *P<0.05; **P<0.01; ***P<0.001 using the unpaired t-test adjusted for multiple comparisons. Two separate experiments with n>5 per group.
tumors in immunocompetent B6 mice, and the tumorigenesis, as we have demonstrated, is facilitated in part by immunomodulation of the tumor microenvironment by the PDVC57 cells via increased arginase activity and decreases in intratumoral effector T cells and dendritic cells.

We demonstrated that transcutaneous arginase inhibition was sufficient to decrease growth of the PDVC57 tumors, in part due to an increase in intratumoral effector T cells and dendritic cells. The involvement of the adaptive immune system was further demonstrated given the lack of anti-tumorigenic effect when nor-NOHA was applied to Rag1 KO mice, which lack mature T and B cells. Somewhat surprisingly, arginase inhibition in immunocompetent B6 mice also resulted in increased PD-1 expression on the intratumoral T cells. The mechanism of this is unclear; one possible pathway is that arginase inhibition leads to the increased activation of T cells with subsequent upregulation of the hyperactivation/exhaustion marker PD-1. The infiltration of PD-1+ T cells have been documented to be a favorable prognostic biomarker in both SCC of the head and neck and melanoma due to their response to checkpoint inhibition therapy. As such, we were able to use systemic administration of the PD-1 inhibitor nivolumab in conjunction with topical nor-NOHA to decrease the rate of tumor growth more than either individual agent alone.

Finally, the development of cSCC due to UV radiation-induced carcinogenesis carries with it the relatively unique concept of field cancerization. Originally described in oropharyngeal SCC, field cancerization in cSCC is defined as the anatomical area adjacent to skin cancers and/or pre-cancers that demonstrate photodamage, and may show histopathologic dysplasia. As such, treatment of only the pre-cancerous and/or cancerous lesions will not address the surrounding dysplastic tissue that carry similar mutational burdens and are likely to

Figure 5. Transcutaneous arginase inhibition significantly reduces growth of PDVC57 tumors in immunocompetent but not immunodeficient mice. (A) Growth curves of treated PDVC57 tumors in immunocompetent B6 mice, with a significant difference by the end of week one. (B) Endpoint tumor weights of treated PDVC57 tumors in immunocompetent B6 mice, with a significant difference. (C) Growth curves of treated PDVC57 tumors in immunodeficient Rag1 KO mice, with no significant differences. (D) Endpoint tumor weights of treated PDVC57 tumors in immunodeficient Rag1 KO mice, with no significant difference. (E) Arginase activity as assessed by enzymatic fluorometric assay of treated PDVC57 tumors in immunocompetent B6 mice, which was significantly different indicating effective inhibition of arginase. (F) Arginase activity in units of catalytic activity (U) as assessed by enzymatic fluorometric assay of treated PDVC57 tumors in immunodeficient Rag1 KO mice, which was significantly different indicating effective inhibition of arginase.

*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 using the unpaired t-test adjusted for multiple comparisons. Three separate experiments with n > 5 per group.
transform into pre-cancerous and/or cancerous lesions in the future\textsuperscript{53}. Current field-directed therapies include 5-fluorouracil, a topical chemotherapeutic agent, and imiquimod, a toll-like receptor 7 agonist\textsuperscript{54}. Topical arginase inhibition may provide an additional avenue of field-directed therapy for cSCC.

In summary, cSCC is the second-most commonly diagnosed cancer in the US and has significant morbidity and mortality rates, especially in high-risk populations. The use of immunotherapy such as checkpoint inhibition for cases of advanced cSCC has shown promise, though a majority of patients do not respond. In this study, we have characterized a pre-clinical injectable immunocompetent mouse model of cSCC and demonstrated the efficacy of topical arginase inhibition in reducing tumorigenesis of cSCC, especially in conjunction with checkpoint inhibitors. These results are promising for the development of future topical adjuvant therapies in the treatment of cSCC.

Methods

Study approval. The ethical use of the animals in this study was in accordance with policies set forth by the United States Department of Agriculture and the Public Health Service. This study was reviewed and approved by the Yale University Institutional Animal Care and Use Committee.

Animals. C57BL/6J and B6.129S7-Rag\textsuperscript{1m1Mom}/J mice were purchased from The Jackson Laboratory. Seven- to ten-week-old female mice were used for all experiments.

Cell lines. PDV cells were a gift of Michael Girardi, MD (Yale University, New Haven, CT). PDVC57 cells were obtained from Department of Cancer Biology, Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid 28029, Spain.

Cell culture and suspension. Cells were cultured in DMEM with pyruvate (GIBCO) and supplemented with 10% FBS (Gemini Bio-Products), 25 mM HEPES, 2 mM l-glutamine, and penicillin/streptomycin (GIBCO). Cell suspensions were made by incubating with trypsin–EDTA (GIBCO) for 10 min, neutralizing, and resuspending in appropriate volumes of PBS.

PDVC57 injection. Mice were anesthetized with ketamine, flanks shaved, and using intradermal injection technique injected in the right flank with 50 μL of PDVC57 cells in suspension.

Tumor measurements. Mice were sedated with isoflurane. Calipers were used to measure tumor diameter. Tumor volume was calculated using the following formula: (tumor length) × (tumor width)\textsuperscript{2} × 0.52, where length is longer than the width.

Topical application of nor-NOHA. 20–50 μL (depending on tumor size) of 5 mM nor-NOHA (EMD Millipore) in DMSO or DMSO control was applied twice daily, starting one day after injection of PDVC57 cells. Tumor sizes were measured as above every other day. At twenty-one days, the mice were euthanized using carbon dioxide and cervical dislocation. The tumors were then dissected out and weighed.
Intravenous infusion of nivolumab. 3 mg/kg nivolumab or isotype control was injected into the retroorbital sinus of the mice once per week, beginning one day after injection of PDVC57 cells. Tumor sizes were measured as above every other day. At twenty-one days, the mice were euthanized using carbon dioxide and cervical dislocation. The tumors were then dissected out and weighed.

Histology and immunofluorescence. Freshly collected tumors were either fixed in 4% paraformaldehyde and embedded in paraffin or placed in optimal cutting temperature compound (OCT). The prepared tumors were cut into 5 μm sections, with the paraffin-embedded sections used for hematoxylin and eosin (H&E) staining and the frozen sections for immunofluorescence. The H&E slides were visualized with light microscopy. The frozen section slides were stained with DAPI and anti-p63 antibody conjugated to FITC (Bioss, bs-0723R-FITC) and scanned with Leica SP5 confocal microscope.

Whole exome sequencing. Exome sequencing and mutational burden analysis were performed according to55. Neoantigen prediction was performed for nonsynonymous SNV, Frameshift, Indel, and Stop-Loss variants that passed MuTect2 quality control filters to create all possible 8mers, 9mers, 10mers, and 11mers using custom Python scripts. Peptide binding affinity of wildtype and mutant peptides to C57BL6/J MHC I alleles H2-Db and H2-Kb were calculated using netMHCCons56.

Tumor processing. In a sterile Petri dish (non-tissue-culture-treated plate), a digestion buffer of 20 mL PBS + Ca²⁺ + 200μL Liberase (5 mg/mL, Roche) + 1 mL DNAse (2 mg/mL, Roche) was prepared. After adding
the tumor to the Petri dish, the tumor was minced with scissors and then more finely with a razor blade. The tumor was then transferred into a 50 mL tube and incubated with shaking for 30 min at 37 °C. The digested tumor was then placed on ice for 3 min with the addition 200 μL of 0.5 M EDTA (GIBCO). The tumor suspension was filtered through a 70 μM cell strainer (Corning, Falcon) into another 50 mL tube. The original tube was washed once with 10 mL of PBS and again filtered through the strainer. The filtered tumor suspension was then centrifuged for 5 min at 1300 RPM at 4 °C. The supernatant was discarded. Between 2 and 10 mL of ACK lysis buffer (GIBCO) was added to lyse red blood cells. After 5 min, the lysis reaction was stopped with approximately 10 mL of PBS + 0.5% FBS (FACS buffer). The resulting suspension was filtered through a 70 μM cell strainer into another 50 mL tube. The filtered contents were centrifuged for 5 min at 1300 RPM at 4 °C. Supernatant was discarded.

Staining for flow cytometry. Fc-block was added to dissociated tumor cell suspensions at 1:200 dilution and incubated for 20 min on ice. Three panels of flow cytometry antibodies were used for leukocyte staining—Panel 1: CD11b-ef450 (M1/70) #48-0112-82 Invitrogen, MHCII-FITC (M5/114.15.2) #11-5321-81, F4/80-AF700 (BM8) #56-4801-82, CD11c-PECy7 (BM8) #56-4801-82 eBioscience, CD45-APC (30-F11) #10311 and Live/Dead-AmCyan (#423101) Biolegend; Panel 2: CD45-PerCP-Cy5.5 (30-F11) #103132, CD3e-APC (145-2C11) #100312, B220 BV605 (RA3-6B2) #103243, PD-1-PE (29F.1A12) #135205, CD4-BV421 (GK1.5) #100437, CD8a-APC Fire 750 (53-6.7) #100766 and Live/Dead-AmCyan (#423101) Biolegend; Panel 3: CD206-FITC (MR5D3) #MA5-16870, CD11b-ef450 (M1/70) #48-0112-82 Invitrogen, F4/80-AF700 (BM8) #56-4801-82 eBioscience, intracellular Arg1-APC (#IC5868A) R&D systems, MHCII-APC-Cy7 (M5/114.15.2) #107652, CD45-PerCP-Cy5.5 (30-F11) #103132 and Live/Dead-AmCyan (#423101) Biolegend.

Flow cytometry analysis. Approximately 200–500 μL FACS buffer were added to the tumor cell pellets in order to resuspend them. Greater volumes were added with a higher number of cells. Cells were analyzed on a LSRII (BD Biosciences).

Arginase activity assay. Arginase activity was detected using the Arginase Activity Colorimetric Assay Kit (BioVision, Milpitas, CA). Tumors were processed as above and lysed in assay buffer at a concentration of 1×10⁶ cells/100 μL. The assay was conducted in accordance with manufacturer instructions. The tumor lysates and background samples were measured in triplicate in a 96 well plate. (Corning, Falcon) The plate was warmed to 37 °C and read at 570 nm (BioTek). Optical density was recorded in kinetic mode every 5 min, beginning at time zero until 60 min, or signal saturation. Arginase Activity (Units [U]) was calculated by fitting the corrected sample reading to the generated standard curve.
Statistics. Some data and graphs were created using Prism 7 (GraphPad Software). Statistical tests were performed as described in the figure legends, and when possible, adjusted P values were used to assess for significance, with a threshold of adjusted \( P < 0.05 \).

This study was carried out in compliance with the ARRIVE 2.0 guidelines.

Received: 2 June 2020; Accepted: 4 May 2021
Published online: 24 May 2021

References

1. Leiter, U., Eigentler, T. & Garbe, C. Epidemiology of skin cancer. Adv. Exp. Med. Biol. 810, 120–140 (2014).
2. Karimkhani, C., Boyers, L. N., DellaValle, R. P. & Weinstock, M. A. It’s time for “keratinocyte carcinoma” to replace the term “nonmelanoma skin cancer”. J. Am. Acad. Dermatol. 72(1), 186–187 (2015).
3. Rogers, H. W. et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch. Dermatol. 146(3), 283–287 (2010).
4. Karin, P. S., Han, J. & Schults, C. D. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J. Am. Acad. Dermatol. 68(6), 957–966 (2013).
5. Mittal, A. & Colegio, O. R. Skin cancers in organ transplant recipients. J. Am. Acad. Dermatol. 72(6), S18–S23 (2015).
6. Euvrard, S., Kanitakis, J. & Claudy, A. Skin cancers after organ transplantation. Dermatol. Surg. 42(Suppl 1), S18–23 (2016).
7. Baur, C. et al. T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin. Cancer Immunol. Immunother. 67(7), 1147–1157 (2018).
8. Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21(8), 938–945 (2015).
9. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12(4), 253–268 (2012).
10. Parker, K. H., Beury, D. W. & Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv. Cancer Res. 128, 95–139 (2015).
11. Ruffell, B. & Crousse, L. M. Macrophages and therapeutic resistance in cancer. Cancer Cell 27(4), 462–472 (2015).
12. Ding, T. et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum. Pathol. 40(3), 381–389 (2009).
13. Zang, B. C. et al. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med. Oncol. 28(4), 1447–1452 (2011).
14. Teng, F. et al. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J. Hematol. Oncol. 9, 8 (2016).
15. Yang, L. & Zhang, Y. Tumor-associated macrophages, potential targets for cancer treatment. Biomark. Res. 5, 25 (2017).
16. Rodriguez, P. C., Ochoa, A. C. & Al-Khami, A. A. Arginine metabolism in myeloid cells shapes innate and adaptive immunity. Front. Immunol. 8, 93 (2017).
17. Morris, S. M. Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br. J. Pharmacol. 157(6), 922–930 (2009).
18. Colegio, O. R. et al. Functional polarization of tumor-associated macrophages by tumour-derived lactic acid. Nature 513(7519), 559–563 (2014).
19. Fuesing, N. E., Dzarlileva-Petrusevska, R. T. & Breitkreutz, D. Phenotypic and cytogenetic characteristics of different stages during spontaneous transformation of mouse keratinocytes in vitro. Carcinog. 9, 293–326 (1988).
20. Zoumpourlis, V., Solaki, S., Papatheo, A. & Papsevangelou, D. Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis. Carcinogenesis 24(7), 1159–1165 (2003).
21. Moll, R., Divo, M. & Langbein, L. The human keratins: biology and pathology. Histochem. Cell Biol. 129(6), 705–733 (2008).
22. Chang, C. I., Liao, J. C. & Kuo, L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res. 61(3), 1100–1106 (2001).
23. Li, B., Cui, Y., Nambiar, D. K., Sunwoo, J. B. & Li, R. The immune subtypes and landscape of squamous cell carcinoma. Cancer Res. 75(19), 5131–5137 (2015).
24. Que, S. K. T., Zwald, F. O. & Schmults, C. D. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumours. J. Am. Acad. Dermatol. 78(2), 249–261 (2018).
25. Mudgett, M. R. et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl. J. Med. 379(4), 341–351 (2018).
26. Hernandez-Guerrero, T., Doger, B. & Moreno, V. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Drugs Today (Barc.) 55(8), 485–494 (2019).
27. Ostrand-Rosenberg, S., Gari, G. & Strati, S. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? Curr. Opin. Oncol. 31(5), 461–468 (2019).
28. Chang, A. L., Kim, J., Luciano, R., Sullivan-Chang, L. & Colevas, A. D. A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor. JAMA Dermatol. 152(1), 106–108 (2016).
29. Borradori, L., Sutton, B., Shayesteh, P. & Daniels, G. A. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basaloid squamous carcinoma: preliminary experience in five cases. Br. J. Dermatol. 175(6), 1382–1386 (2016).
30. Winkler, J. K. et al. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br. J. Dermatol. 176(2), 498–502 (2017).
31. Rodriguez, P. C., Quienio, D. G. & Ochoa, A. C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109(4), 1568–1573 (2007).
32. Wu, C. W. et al. Serum arginase level in patients with gastric-cancer. J. Clin. Gastroenterol. 18(1), 84–85 (1994).

www.nature.com/scientificreports/
40. Ochoa, A. C., Zea, A. H., Hernandez, C. & Rodriguez, P. C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. *Clin. Cancer Res.* 13(2), 721s–726 (2007).

41. Vasquez-Dunddel, D. et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. *J. Clin. Investig.* 123(4), 1580–1589 (2013).

42. Abel, E. L., Angel, J. M., Kiguchi, K. & DiGiovanni, J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. *Nat. Protoc.* 4(9), 1350–1362 (2009).

43. Kemp, C. J. Multistep skin cancer in mice as a model to study the evolution of cancer cells. *Semin. Cancer Biol.* 15(6), 460–473 (2005).

44. Yuspa, S. H. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. *J. Dermatol. Sci.* 17(1), 1–7 (1998).

45. Brown, K. et al. v-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis. *Cell* 46(3), 447–456 (1986).

46. Navarro, P. et al. A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis. *J. Cell Biol.* 115(2), 517–533 (1991).

47. Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *N. Engl. J. Med.* 366(3), 207–215 (2012).

48. Buchmann, A., Ruggeri, B., Klein-Szanto, A. J. & Balmain, A. Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. *Cancer Res.* 51(15), 4097–4101 (1991).

49. Badoual, C. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. *Cancer Res.* 78(1), 128–138 (2013).

50. Grob, A. et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. *J. Clin. Invest.* 124(5), 2246–2259 (2014).

51. Nart, I. F. et al. Defining the actinic keratosis field: a literature review and discussion. *J. Eur. Acad. Dermatol.* 32(4), 544–563 (2018).

52. Slaughter, D. P., Southwick, H. W. & Smejkal, W. Field cancerization in oral stratified squamous epithelium—clinical implications of multicentric origin. *Cancer* 65(5), 963–968 (1953).

53. Christensen, S. R. Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas. *F1000Res* 7, 690 (2018).

54. Philipp-Dormston, W. G. Field cancerization: from molecular basis to selective field-directed management of actinic keratosis. *Curr. Probl. Dermatol.* 46, 115–121 (2015).

55. Wang, J. et al. UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. *Pigment Cell Melanoma Res.* 30(4), 428–35 (2017).

56. Karosiene, E., Lundegaard, C., Lund, O. & Nielsen, M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. *Immunogenetics* 64(3), 177–186 (2012).

Acknowledgements

Oscar R. Colegio, MD, PhD was supported by the National Cancer Institute (1K08CA172580) and The Lawrence F. and Joan Castellani Family Endowed Chair in Dermatology. The authors would like to acknowledge Adeleye Opejin, PhD, for his support and critical review of this manuscript.

Author contributions

Study concept and design: A.M., M.W., A.V., O.R.C. Acquisition, analysis, and interpretation of data: A.M., M.W., A.V., D.Y., G.P., E.T., O.R.C. Statistical analysis: A.M., M.W., D.T. Obtained funding: O.R.C. Study supervision: O.R.C. Manuscript for important intellectual content: A.M., M.W., A.V., D.Y., G.P., E.T., O.R.C. Reprints and permissions information is available at www.nature.com/reprints.

Correspondence

The authors declare no competing interests.

Additional information

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-90200-y.

**Correspondence**

and requests for materials should be addressed to M.W. or O.R.C.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021